Status:
UNKNOWN
Association of Cystatin C and Bone Mineral Density in Diabetic Patients.
Lead Sponsor:
Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions:
Osteoporosis
Osteoporosis, Postmenopausal
Eligibility:
All Genders
50+ years
Brief Summary
Type 1 diabetes is associated with low bone mineral density(BMD) and type 2 diabetes with normal or high BMD. Cystatin C is a small molecule that is used to measure kidney function but it's not a tro...
Detailed Description
This is a cross-sectional study of adults with diabetes to determine the association of cystatin C with bone mineral density(BMD). All the inpatient in the department of endocrinology and metabolism i...
Eligibility Criteria
Inclusion
- Type 1 or type 2 diabetes male / female, older than 50 years old.
Exclusion
- Use of any drug that affects bone metabolism (bisphosphonate, denosumab, teriparatide, steroids, anticancer drugs, thyroid hormones, antidepressants, antiretrovirals, calcium, vitamins A/D)
- Any disease affecting bone minerals (hyperthyroidism, hypothyroidism, parathyroid disease, Cushing's disease, rickets/osteomalacia, collagen disorders, rheumatoid arthritis)
- Kidney disease, urinary albumin-creatinine ratio greater than 30 mg / g or GFR \<60ml / min / 1.73m2.
Key Trial Info
Start Date :
July 4 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 25 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04019938
Start Date
July 4 2019
End Date
December 25 2019
Last Update
July 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ashish Shrestha
Zhuhai, Guangdong, China, 15000